EntreMed (ENMD) Misses Q3 Royalty Estimates From Thalomid Sales, Anticipates Decrease in Q4 & FY09 Revenue
Tweet Send to a Friend
EntreMed (Nasdaq: ENMD) announced the receipt of $1.7 million in royalty revenue from sales of Thalomid during the third quarter ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
